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Abstract 
OBJECTIVE: 
Our objective was to evaluate the impact of low versus borderline MIC of piperacillin/tazobactam on the 
clinical outcomes of patientswith bacteraemia caused by Enterobacteriaceae who were treated with that 
antimicrobial. 
PATIENTS AND METHODS: 
A prospective observational multicentre cohort study was conducted in 13 Spanish university 
hospitals. Patients >17 years old with bacteraemia due to Enterobacteriaceae who received 
empirical piperacillin/tazobactam treatment for at least 48 h were included.Outcome variables were 
clinical response at day 21, clinical response at end of treatment with piperacillin/tazobactam and all-
cause 30 day mortality. Univariate and multivariate logistic regression analyses were performed. 
RESULTS: 
Overall, 275 patients were included in the analysis; 248 (90.2%) in the low MIC group (≤ 4 mg/L) and 27 
(9.8%) in the borderline MICgroup (8-16 mg/L). The biliary tract was the most common source of infection 
(48.4%) and Escherichia coli was the most frequent pathogen (63.3%). Crude 30 day mortality rates were 
10.5% and 11.1% for the low MIC group and the borderline MIC group, respectively (relative risk = 1.06, 
95% CI = 0.34-3.27, P = 1). Multivariate analysis of failure at day 21 and at end of treatment 
with piperacillin/tazobactam and 30 day mortality showed no trend towards increased clinical failure or 
mortality with borderline MICs (OR = 0.96, 95% CI = 0.18-4.88, P = 0.96; OR = 0.47, 95% CI = 0.10-2.26, 
P = 0.35; OR = 1.48, 95% CI = 0.33-6.68, P = 0.6). 
CONCLUSIONS: 
We did not find that higher piperacillin/tazobactam MIC within the susceptible or intermediate 
susceptibility range had a significant influence on the outcome for patients with bacteraemia due 
to Enterobacteriaceae. 
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